Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

Bernhard ScheinerMartha M KirsteinFlorian HuckeFabian FinkelmeierKornelius SchulzeJohann von FeldenSandra KochPhilipp SchwablJan B HinrichsFredrik WaneckOliver WaidmannThomas ReibergerChristian MüllerWolfgang SieghartMichael TraunerArndt WeinmannHenning WegeJörg TrojanMarkus Peck-RadosavljevicArndt VogelMatthias Pinter

Published in: Alimentary pharmacology & therapeutics (2019)

Programmed cell death protein-1-targeted immunotherapy with nivolumab or pembrolizumab showed promising efficacy and safety in patients with advanced hepatocellular carcinoma, including subjects with Child-Pugh stage B and patients with intensive pretreatment.

Keyphrases

cancer therapy
protein protein
amino acid
binding protein
small molecule
randomized controlled trial
machine learning
advanced non small cell lung cancer
drug delivery
double blind
deep learning